Press Releases

Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 AUSTIN, Texas , March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on

AUSTIN, Texas , March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34 th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in

AUSTIN, Texas , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022 .

AUSTIN, Texas , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022 .

AUSTIN, Texas , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferences:   Event:   Stifel 2021 Virtual

Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sites Six-month primary outcome data readout from OraGrowtH210 expected 2H 2023 AUSTIN, Texas , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.

AUSTIN, Texas , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2021 financial results after market close on Wednesday, November 3, 2021 .

AUSTIN, Texas , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23 rd Annual Global Investment Conference and the Cantor

• Lumos Pharma strengthens leadership team with promotion of John McKew , PhD to President, and addition of David B. Karpf , MD as Chief Medical Officer and Mark Bach , MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress AUSTIN, Texas , Aug.